CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
Alfuzosin +1 moredrug
Likely dose
Alfuzosin 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01834729
NCT01834729Phase 2Completed
CompareCT.gov

Effect of Stress and a Alpha-1 Antagonist on Anorectal Functions

Mayo Clinic·interventional·Posted Apr 18, 2013·Updated Jan 29, 2019

In Brief

A Phase 2 clinical trial evaluating Alfuzosin and Placebo for Constipation. Completed, enrolled 74 participants across 1 site.

Detailed Summary

This study is designed to better understand the effects of effects of stress, relaxation, and a medication alfuzosin on bowel control and emptying in healthy people and patients with bowel problems.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation
CountriesUnited States
CollaboratorsNational Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 18, 2013
Enrollment StartMar 1, 2013
Primary CompletionSep 6, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.2 years ago

Interventions

Alfuzosindrug

oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)

Placeboother

placebo capsule identical to the study drug